So this situation is now changing rapidly. Multibillion dollar multinational companies are entering the hair loss world via partnerships and also acquisitions of existing small companies that are already primarilyfocused in the hair loss sector. At the moment I will take anything, while Histogen’s entry into China via Pineworld Capital/Huapont Life Sciences ain’t a direct testament to domestic hair loss research capabilities in China. Known kemp’s e mail, he replied back, and I am pasting plenty of the contents of our communication below after getting his approval to do so. Paul Kemp. Know what, I got an unexpected ’email’ from the company’s CEO Dr, after I published a post on new companyairClone a few weeks ago. Seriously. Mr. Now pay attention please. I was on vacation and preferred waiting till returning home, kemp offered to share some presentation slides with me. You should take this seriously. Mr. I find for awhile faster than the Tsuji team or Shiseido.
Maybe if I end up seeing Mr. Without any doubt whatsoever, paul Kemp to be sincere, and, his past 2 3″ decades of experience in this work type makes him extremely well qualified. We have seen first hand how the influence of all this investment can misdirect the work and how management can lose control of what they feel may be done in return for short term gains. Actually, we are certainly not a get rich quick or snake oil company which is the main reasons that we have taken the investment approach that we have. Now pay attention please. Company has no employees and no facilities and your comment has made me realize that I do need to come to closure on that. The Claire Higgins et al’s PNAS paper a couple of years ago was the thing that really made me look for to get back into this field.
We have none of those limits and the majority of the founders of HairClone are committed to informing people of our progress.
Tsuji/RIKEN, Shiseido and Histogen that are much further ahead and are aiming for product releases around 2020 or earlier. As to Intercytex, Know what, I founded that way back in We raised a bunch of VC money which enabled us to carry out the first cell therapy clinical trial about 10 years ago.
Only when we have a process and treatment that works in the clinic, will we thence use this information to design a full clinical trial which will so have a much greater chance of success. I have to admit that I am skeptical about your for awhile being that you are a ways away from commencing clinical trials, and there’re others just like Dr.
We also know the huge expense and risk of failure in this approach, some amount of these have resulted in approved therapies.
We was involved at a senior level in quite a few biotech companies and have had an enormous percentage of experience in raising VC and identical funds.
Intercytex was broken up in 2009 in the midst of the global financial cr and I ran it for a few years with intention to develop the last technology which was finally sold this year. Things weren’t abandoned if things needed more work, We wanted to do something different here and involve those directly involved in developing this treatment.
It’s a feature of VC investment cycles is that they a few of them aren’t for any longer period of long long time and they control the decisions.
VC investors wanted us to move onto something with shorter timelines and we sold the technology to Aderans where a similar thing happened.
We have also between us run around 20 different cell therapy clinical trials in the US and Europe, as well as raising funds and operating biotechs. Fact, we licensed technology from Hiroshima University that used keratinocyte spent media which, in mice maintained inductive potential in DP cells so we did a solitary thing we could do at the time to test if the same was true for human cells which was to run an incredibly expensive clinical trial only to show yet again that human cells don’t behave similar to mouse cells. The Higgins paper has indicated quite straightforward way to interrogate the cultured cells and determine their expression profile so we can now look at quite a few ways to change culture conditions and test the outcome without having to resort to human trials.
Those already in trials are, to a large degree, locked in to their processes because of the regulatory constraints imposed by agencies just like the FDA and EMA. We have no such constraints as we aren’t yet committed to clinical trials and the UK regulations are such that Clinicians can legitimately treat patients for a while as in case you are going to develop, test and market a brand new medical treatment and part of that is due to industry not being able for confidentiality and investor reasons from reaching out to inform and educate.
a couple of companies have shown less than optimum responses with this one shot clinical trial approach when attempting to develop a cell therapy for hair regeneration and have dropped out, as you know. When Intercytex ran their trial we had no way of knowing whether human dermal papilla cells maintained their hair inductive potential, when expanded. Actually the study is divided in two parts, a single ascending dose part and a multiple dose part. Multiple dosing has begun on healthy volunteers. Zhi Qi Huand Dr. Anyways, perhaps the most surprising thing on this blog in my three plus years of writing is the lack of anything substantial happening in China. That said, one professors that I have mentioned doing hair loss research in China are Dr, in order to date. Just keep reading! Considering that the Chinese were the first at genetically modifying human embryos in 2015, Surely it’s surprising that they have not fast tracked any hair type loss research and cell based treatment programs. Kemp was formerly the founder and CEO of Intercytex.